Traders should anticipate increased investor confidence and potential share price upside as this data positions AstraZeneca to expand its dominance in liver cancer. Regulatory submissions are likely imminent, with commercial launch possible within 12–18 months. Monitor upcoming medical conference presentations for full data, which could further validate clinical benefit and inform peak sales estimates.
AZN drugs
AZN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 2 $203.30entry
- T+1 · 7mo ago −0.29%α −0.76% · $202.72
- T+5 · 7mo ago +0.32%α −3.29% · $203.96
- T+20 · 7mo ago −7.83%α −17.71% · $187.37
- T+60 · 5mo ago −6.07%α −19.06% · $190.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AstraZeneca announced positive Phase III EMERALD-3 trial results showing that the combination of Imfinzi and Imjudo with lenvatinib and TACE significantly improved progression-free survival (PFS) in patients with embolisation-eligible unresectable liver cancer. The data, which also show a trend toward improved overall survival, support a potential new standard of care in earlier-stage hepatocellular carcinoma (HCC) and are being shared with regulators.
Key Facts
- EMERALD-3 Phase III trial met primary endpoint: statistically significant and clinically meaningful improvement in PFS for Imfinzi + Imjudo + lenvatinib + TACE vs TACE alone in unresectable HCC.
- Interim analysis shows trend toward improved overall survival (OS), a key secondary endpoint.
- Trial included 760 patients across 171 centers in 22 countries.
- STRIDE regimen (durvalumab + tremelimumab) forms the immunotherapy backbone; builds on prior HIMALAYA trial success in advanced HCC.
- No new safety signals observed; safety profile consistent with known drug profiles.
- Data will be presented at a future medical meeting and submitted to global regulatory authorities.
Financial Impact
High commercial potential: over 200,000 patients annually eligible for embolisation in HCC represent a significant market opportunity. This could expand Imfinzi/Imjudo's label into earlier-stage disease, driving meaningful revenue growth.
Risk Factors
- Final overall survival data remain immature and could diverge from current trends.
- Regulatory approval may require additional data or longer follow-up.
- Competition from other IO combinations or emerging therapies in HCC could limit market penetration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003206 |
| Document: 0001654954-26-003206-index-headers.html | 0001654954-26-003206 |
| Document: 0001654954-26-003206-index.html | 0001654954-26-003206 |
| Document: 0001654954-26-003206.txt | 0001654954-26-003206 |
Track record
77 reports on AZN
18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
- Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers